This site is intended for healthcare professionals only
LoginRegister
Indobufen

Indobufen

Indications, Uses, Dosage, Drugs Interactions, Side effects
Indobufen
Medicine Type :
Allopathy
Prescription Type:
Prescription Required
Approval :
DCGI (Drugs Controller General of India)
Schedule
Schedule H
Pharmacological Class:
Nonsteroidal Anti-inflammatory Drugs (NSAIDs),
Therapy Class:
Analgesic, Anti-inflammatory Agent,

Indobufen is Non- Steroidal Ant inflammatory Drugs belonging to Analgesic and Anti inflammatory agents.

Indobufen is used in the Management of Thromboembolic disorders

Indobufen is Rapidly absorbed; peak plasma concentrations in 2 hr with Protein-binding of 99%. It undergoes Hepatic metabolism.

and get excreted Via urine (75%, as metabolites and unchanged drug); 8 hr (plasma half-life).

Indobufen is available in Tablets.

Indobufen is available in India, Germany, Canada, France, USA.

Indobufen inhibits platelet aggregation by reversibly inhibiting the platelet cyclooxygenase enzyme thereby suppressing thromboxane synthesis.

Indobufen is available in the form of tablets.

Indobufen is used in the Management of Thromboembolic disorders.

Indobufen inhibits platelet aggregation by reversibly inhibiting the cyclo-oxygenase enzyme, resulting in suppressed thromboxane synthesis.

Indobufen is approved for use in the following clinical indications

Thromboembolic disorders

Thromboembolic disorders

Adult: 200-400 mg/day in 2 divided doses. May also be given parenterally using the sodium salt.

Elderly: >65 yr: 100-200 mg/day.

Indobufen is available in the dosage strength of

Tablet

  • 100mg
  • 200mg

Indobufen is available in the form of Tablets.

GI ulceration, ulcerative colitis, active bleeding, haemophilia.

Reduced absorption with antacids and cholestyramine.

  • Pharmacodynamic

Indobufen inhibits platelet aggregation by reversibly inhibiting the platelet cyclooxygenase enzyme thereby suppressing thromboxane synthesis.

  • Pharmacokinetics

Absorption: Rapidly absorbed; peak plasma concentrations in 2 hr.

Distribution: Protein-binding: 99%.

Metabolism: Hepatic.

Excretion: Via urine (75%, as metabolites and unchanged drug); 8 hr (plasma half-life).

There are some clinical studies of the drug mentioned below:
  1. https://pubmed.ncbi.nlm.nih.gov/1091001/
  2. https://clinicaltrials.gov/ct2/show/NCT01422915
  3. https://clinicaltrials.gov/ct2/show/NCT02263547
  4. https://www.medicines.org.uk/emc/product/128/smpc.
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1364710/
  • https://reference.medscape.com/drug/colestid-Indobufen -342452
  • https://go.drugbank.com/drugs/DB00375
  • https://www.sciencedirect.com/topics/medicine-and-dentistry/Indobufen
  • https://europepmc.org/article/med/6988203
undefined
Parthika Patel
Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
undefined
Dr JUHI SINGLA
Dr JUHI SINGLA has completed her MBBS from Era’s Lucknow Medical college and done MD pharmacology from SGT UNIVERSITY Gurgaon. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
Published on: 4 July 2023 2:39 PM GMT
X